Why Verve Therapeutics Is Skyrocketing Today

Verve Therapeutics (NASDAQ: VERV) stock is seeing explosive gains Tuesday. The biotech company's share price was up 24.5% as of 12:30 p.m. ET and had been up as much as 41% earlier in the session.Yesterday, Verve published promising data from its Heart-2 Phase 1b clinical trial of its VERVE-102 treatment for heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease. Several analysts have now raised their price targets on the stock, and investors are buying up shares in response. In coverage published this morning, Cantor Fitzgerald raised its rating on Verve Therapeutics stock from neutral to overweight -- indicating that the firm thinks the stock is a good buy. The firm's analysts said that results for VERVE-102 had come in better than expected in terms of both safety and efficacy.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool